MedTrace Logo

Epidemiology of Gout in French Polynesia

NCT04812886 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1088

Last updated 2026-04-21

No results posted yet for this study

Summary

Gout is a chronic disease caused by the deposit of monosodium urate (MSU) crystals in body tissues secondary to hyperuricemia. Patients with gout suffer severe attacks of acute joint pain. As the disease progresses, the joint pain becomes chronic and associated with disabling and deformative manifestations called tophi. Gout is strongly associated with various comorbidities including cardiovascular disease and chronic kidney failure. Gout is a very common disease, affecting 0.9% of the adult population in France and nearly 4% of the North-American population. Data from New Zealand show a particularly high prevalence of gout among Polynesians (minority populations in New Zealand and other islands of the South Pacific) that would be explained by genetic susceptibility and frequently intertwined with metabolic diseases. Recent findings obtained from the Polynesian population in New Caledonia disclose high prevalence figures close to 7%, a level expected to be confirmed by an epidemiology study that will be conducted in parallel with the present study and designed to determine the precise prevalence of gout in French Polynesia and the most frequently associated genetic variants.

Conditions

Interventions

OTHER

Epidemiological study

Questionnaires (quality of life, gout, life habit, comorbidities) anthropometrics and health measures DNA analysis RNA analysis Metabolomic analysis

Sponsors & Collaborators

  • Variant Bio, Inc.

    collaborator UNKNOWN

  • University of Birmingham

    collaborator OTHER

  • University of San Diego

    collaborator OTHER

  • Ministry of Health, French Polynesia

    collaborator UNKNOWN

  • Lille Catholic University

    lead OTHER

Principal Investigators

  • Tristan Pascart, MD, PhD · GHICL

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-29
Primary Completion
2021-08-16
Completion
2021-08-16

Countries

  • French Polynesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04812886 on ClinicalTrials.gov